Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer
Phase II Clinical Study of Patients Randomized, Open, Controlled Evaluation of Autologous Tumor Tissue Antigen Sensitized DC-CIK Cells Combined With Chemotherapy in the Treatment of Patients With Esophageal Resection
Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University
This PHASE2 trial investigates Digestive System Neoplasms and Esophageal Cancer and is currently ongoing. Affiliated Cancer Hospital & Institute of Guangzhou Medical University leads this study, which shows 6 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- Shenzhen Hornetcorn Bio-technology Company, LTD
For direct contact, visit the study record on ClinicalTrials.gov .